Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 12/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 12/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 12/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 12/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17354662 | 0.88 | ADORA2A (0.48) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL17354759 | 0.77 | XDH (0.56) | — | |
| SCHEMBL27599134 | 0.70 | GSK3B (0.69) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5146335 | 0.67 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5360808 | 0.67 | ADORA2A (0.59) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL17802561 | 0.67 | CFTR (0.66) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL458772 | 0.66 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL4449476 | 0.66 | PI4KA (0.45) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL588905 | 0.66 | TDP1 (0.44) | ALDH1A1ADORA2AHIF1A | |
| SCHEMBL2346678 | 0.65 | GSK3B (0.67) | PI4KAPI4K2BPI4K2API4KBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370362-B2 | Pyrazine derivatives with extended conjugation and methods of using the same in optical applications | MEDIBEACON INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190194172-A1 | PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND METHODS OF USING THE SAME IN OPTICAL APPLICATIONS | MEDIBEACON INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-20160090376-A1 | PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND METHODS OF USING THE SAME IN OPTICAL APPLICATIONS | MALLINCKRODT INC. | 2016-03-31 | — | — | US | disclosed |
| US-9216963-B2 | Pyrazine derivatives with extended conjugation and methods of using the same in optical applications | MEDIBEACON INC. (US) | 2015-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370362-B2 | Pyrazine derivatives with extended conjugation and methods of using the same in optical applications | CYP3A5, PAICS, CYP3A43 | PI4KA 3810/4885PI4K2B 3876/4885PI4K2A 3621/4885 |
| US-20160090376-A1 | PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND METHODS OF USING THE SAME IN OPTICAL APPLICATIONS | CYP3A5, PAICS, CYP3A43 | PI4KA 3810/4885PI4K2B 3876/4885PI4K2A 3621/4885 |
| US-20190194172-A1 | PYRAZINE DERIVATIVES WITH EXTENDED CONJUGATION AND METHODS OF USING THE SAME IN OPTICAL APPLICATIONS | CYP3A5, PAICS, CYP3A43 | PI4KA 3810/4885PI4K2B 3876/4885PI4K2A 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.